Loading...
•
Dec 31, 2024
Stoke Therapeutics Q4 2024 Earnings Report
Stoke Therapeutics reported its Q4 2024 financial results with strong revenue growth from collaboration agreements but continued to report a net loss driven by R&D and operational investments.
Key Takeaways
In Q4 2024, Stoke Therapeutics reported $22.6 million in revenue from license and collaboration agreements. The company incurred a net loss of $10.5 million and continued investing heavily in R&D and administrative functions. With $246.7 million in cash and marketable securities, the company has a solid cash runway extending to mid-2028.
Revenue for Q4 2024 was $22.6 million, a substantial increase from $2.8 million in Q4 2023.
Net loss narrowed to $10.5 million compared to $27.0 million in the prior year period.
R&D expenses increased to $23.4 million, reflecting continued development activities.
Cash and cash equivalents stood at $127.98 million, with $246.7 million including marketable securities.
Stoke Therapeutics
Stoke Therapeutics
Stoke Therapeutics Revenue by Segment
Revenue by Segment
Acadia Pharm. Revenue
CapyFin.com Forward Guidance
Stoke Therapeutics anticipates initiating the Phase 3 EMPEROR study in Q2 2025 and expects continued investment in clinical development and strategic collaborations.
Positive Outlook
- Phase 3 EMPEROR study on track for Q2 2025 initiation.
- Strong financial position with funding secured through mid-2028.
- Positive regulatory alignment with FDA, EMA, and Japanese authorities.
- Ongoing partnership with Biogen to accelerate global commercialization.
- Continued progress in open-label extension studies with promising results.
Challenges Ahead
- Ongoing net losses due to high R&D and operational expenses.
- Potential delays or risks in clinical trial outcomes.
- Market uncertainty impacting collaboration proceeds.
- Regulatory risks tied to investigational treatments.
- Significant dependency on zorevunersen's success for future revenue growth.